Suchbegriffe: LORLATINIB, . Treffer: 2
Hochmair, MJ; Fabikan, H; Illini, O; Weinlinger, C; Setinek, U; Krenbek, D; Prosch, H; Rauter, M; Schumacher, M; Wöll, E; Wass, R; Brehm, E; Absenger, G; Bundalo, T; Errhalt, P; Urban, M; Valipour, A
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.
PHARMACEUTICALS-BASE. 2020; 13(11):
Doi: 10.3390/ph13110371
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Hochmair, MJ; Weinlinger, C; Fabikan, H; Illini, O; Krenbek, D; Setinek, U; Watzka, S; Koger, R; Meilinger, M; Absenger, G; Wanke, M; Semmelweis, C; Rauter, M; Valipour, A
Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients
J THORAC ONCOL. 2019; 14(10):S847-S847.
Doi: 10.1016/j.jtho.2019.08.1831
[Poster]
Web of Science
FullText
FullText_MUG